Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)


Carfilzomib/Lenalidomide/Dexamethasone (CRd) as Initial Therapy for Patients with Newly Diagnosed Multiple Myeloma (MM)
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview
with Rafael Fonseca, MD (12/22/10)

Jakubowiak AJ et al. Carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma: Initial results of Phase I/II MMRC trial. Proc ASH 2010;Abstract 862.

Dr Fonseca is Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.